Aduro BioTech Inc (NASDAQ:ADRO) insider Stephen T. Isaacs sold 7,949 shares of the firm’s stock in a transaction dated Friday, January 5th. The stock was sold at an average price of $7.95, for a total transaction of $63,194.55. Following the completion of the sale, the insider now owns 213,695 shares of the company’s stock, valued at $1,698,875.25. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
Aduro BioTech Inc (ADRO) opened at $6.75 on Wednesday. Aduro BioTech Inc has a one year low of $6.01 and a one year high of $14.05. The firm has a market cap of $552.72, a price-to-earnings ratio of -4.96 and a beta of 3.52.
Aduro BioTech (NASDAQ:ADRO) last released its earnings results on Tuesday, October 31st. The biotechnology company reported ($0.33) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.03). The firm had revenue of $3.79 million for the quarter, compared to analysts’ expectations of $4.04 million. Aduro BioTech had a negative net margin of 548.92% and a negative return on equity of 39.28%. The firm’s quarterly revenue was up .0% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.54) EPS. analysts forecast that Aduro BioTech Inc will post -1.28 earnings per share for the current year.
Several brokerages recently weighed in on ADRO. William Blair reissued an “outperform” rating on shares of Aduro BioTech in a research report on Monday, October 2nd. HC Wainwright reaffirmed a “buy” rating and issued a $18.00 target price on shares of Aduro BioTech in a research report on Wednesday, September 27th. Oppenheimer started coverage on shares of Aduro BioTech in a research report on Monday, October 30th. They issued a “buy” rating and a $15.00 target price for the company. BidaskClub downgraded shares of Aduro BioTech from a “hold” rating to a “sell” rating in a research report on Saturday, December 9th. Finally, Canaccord Genuity set a $30.00 target price on shares of Aduro BioTech and gave the stock a “buy” rating in a research report on Thursday, December 14th. One research analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $17.71.
WARNING: “Stephen T. Isaacs Sells 7,949 Shares of Aduro BioTech Inc (ADRO) Stock” was originally reported by BBNS and is the property of of BBNS. If you are reading this news story on another domain, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this news story can be viewed at https://baseballnewssource.com/markets/aduro-biotech-inc-adro-insider-stephen-t-isaacs-sells-7949-shares-of-stock/1822101.html.
Aduro BioTech Company Profile
Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.
Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.